The prognostic value of hormone receptor detection by enzyme immuno assay and immunohistochemistry; a prospective study in patients with early breast cancer. 
INTRODUCTION
Oestrogen-(ER) and progesterone-receptors (PR) are routinely used in the clinical management of breast cancer. The main reason to determine ER and PR is their predictive value for response to hormonal therapy. 1, 2 It has been noted that oestrogen-and progesterone-receptors are also weak prognostic factors.
However, long-term disease free and overall survival are not significantly influenced by the hormone receptor status. 3 There are three commonly used techniques for hormone receptor determination.
Until recently the ligand binding assay (LBA) has been the most commonly used method. With this method the rates of binding affinity and capacity of a radioactively labelled steroid hormone with its receptors in cytosol are measured.
Nowadays most hospitals in the Netherlands use immunocytochemical assays (ICA) for determination of the presence of hormone receptors in tumour cells.
With this qualitative technique highly specific monoclonal antibodies directed against the partially purified receptor are used. ICA has advantages over LBA: it is more sensitive and specific in the identification of low concentrations of hormone receptor positive tumour cells or in identifying hormone receptors in benign epithelium under direct microscopic visualization. 4, 5 Several efforts have been made to (semi-)quantify ICA results. Good intra-and inter-observer reproducibility have been reported. 6, 7 McClelland et al., however, compared the quantitative analyses of eight experienced, independent pathologists in the interpretation of ER and PR immunocytochemically stained breast tumour sections and observed a high interobserver variability. 8 The method of enzyme immunoassay (EIA) also uses specific monoclonal antibodies for hormone receptor determination, but in a quantitative way. It therefore shares many of the advantages of LBA and ICA. However, it lacks the control of presence or absence of receptor proteins in tumour cells. Concordance rates of 75% -85% and correlation coefficients of 0.70 -0.97 between EIA, ICA and LBA have been reported and are found to be acceptable. [5] [6] [7] [9] [10] [11] [12] [13] [14] [15] [16] [17] The predictive and prognostic values both of EIA and of ICA appear of the same magnitude compared with that of LBA. 11, 18, 19 The prognostic value of ICA and EIA have not been compared with each other. To our knowledge there has been only one study comparing the predictive value of EIA and ICA. 15 In the present study we prospectively evaluated the prognostic value detected both by ICA and by EIA of ER in 223 and of PR in 207 breast cancer patients after a median follow-up of 86 months. 
PATIENTS AND METHODS

Patients and primary treatment
Immunocytochemical assay
ER-and PR-determination by ICA were performed at the local pathology department on fresh frozen tumour-tissue. ER-ICA and PR-ICA were performed according to the instructions of the manufacturer (Abbott Laboratories, Chicago, IL, USA) using monoclonal rat antibodies to respectively human ER and PR.
Tumours were considered hormone receptor positive if more than 10% of tumour cells showed positive staining. 11, 12, 16 In this study ICA data were obtained from routine pathology reports and are therefore reported as positive or negative. 
RESULTS
In the present registration study 463 patients were suitable for survival analysis.
Both ER-EIA and ER-ICA were determined in 223 patients. The remaining 240 patients were used as control group in order to exclude selection bias. Both PR-EIA and PR-ICA were determined in 207 patients; the other 256 patients were used as a control group. Treatment modalities and tumour characteristics in the study groups were compared with those of the control groups (Table 4 .1). Breast conserving therapy was performed in 55% -60%, mastectomy in 38% -43% of patients. Local excision only was done in 2% of patients. Radiation therapy was administered in 64% -67% of patients, and adjuvant chemotherapy in 15% -16%
of patients. The percentage of patients that received adjuvant hormonal therapy was higher in the groups in whom both ER-EIA and ER-ICA were determined compared to the control group, 35% vs. 27%. Of 21 patients in whom ER was not determined by ICA or EIA, 7 (33%) received adjuvant hormonal therapy. In the study group hormonal therapy was not given significantly more in ER-positive tumours compared to ER-negative tumours (table 4. 2). The control groups contained significantly more small tumours with a diameter < 11 mm compared to the study groups (22% vs. 11%). In all groups almost 60% of tumours were less than 2 cm in diameter, 55% -61% of tumours were axillary lymph node negative. 
4). No
differences were found between study-and control groups. Three, 5 and 7 year DFI was 86%, 81% and 75% respectively. DFI-rates in hormone receptor positive patients were slightly higher compared to hormone receptor negative patients.
These differences were not statistically significant. Three, 5 and 7 year OS was 93%, 87% and 80% respectively. Differences between OS-rates in hormone receptor positive and negative patients were greater and frequently statistical significant (Table 4. Between 1989 and 1993 in total 463 early breast cancer patients were included in a multicentre, prospective registration study on prognostic factors. ER and PR could be determined both by EIA and by ICA in less than 50% of patients (48% and 45% respectively). In order to evaluate a potential bias, the remaining patients in whom ICA and/or EIA were not determined were used as a control group. Most tumour characteristics and primary treatment modalities differed not significantly between the study and the control groups. However, the percentage of patients that received adjuvant hormonal therapy was higher in the ER-study group compared with that of the ER-control group. We could not find a suitable explanation for this phenomenon. Treatment selection based on hormone receptor values is not likely since hormonal therapy was not given significantly more in ER-positive tumours compared with that of ER-negative tumours. In tumours in which the ER was not determined at all, hormonal therapy was provided to 33% of patients. At the time of patient inclusion hormone receptors were not used as predictive factor. The rate of small tumours (< 11 mm.) was significantly higher in the control groups compared to the study groups. This was at least partly due to selection, since it is not possible to perform an adequate and reliable EIA in micro-invasive cancer. However, the consequences of this bias appear to be low. During follow-up the rate of events did not differ significantly between study-and control groups. No differences in Cox-regression analyses and in 3, 5 and 7 year survival rates were found between study-and control groups either. Therefore, we conclude that the groups of patients in whom ER and PR were determined were representative for the whole population of breast cancer patients. borderline EIA and ICA results. 13 The major theoretical advantage of ICA over EIA is microscopic verification of the presence of the receptor proteins in tumour cells.
It has been suggested that ICA is a more specific and more sensitive test for the measurement of receptor content in breast cancer. 12 It is, however, impossible to draw conclusions concerning specificity and sensitivity and the discordant results in the present study.
After 7 years of follow-up ER-ICA, ER-EIA and PR-ICA were significant prognosticators of OS. Significance remained after stratification for adjuvant hormonal therapy. No significance was found for DFI though. The absence of prognostic significance in the present study for DFI was not unexpected. The number of patients studied was relatively small. ER and PR are considered to be weak prognostic factors. 2 The observed prognostic significance of the hormone receptors for OS was probably caused by a better response in relapsed disease to hormonal treatment of patients with initial hormone receptor positive tumours.
Although long-term DFI and OS are thought not to be significantly influenced by the hormone receptor content, hormone receptor positive tumours are thought to have a somewhat more indolent course during the first few years after primary treatment. 2 This could not be supported by the differences in DFI-rate and OSrate between hormone receptor negative and positive tumours at 3, 5 and 7 year, as they appeared to be constant over time and independent upon time-point of analysis.
The major theoretical advantage of EIA over ICA is its objective quantification.
Several efforts have been made to (semi-)quantify ICA results and good intraand inter-observer reproducibility has been reported by several authors. 6, 7 Others, however, observed a high interobserver variability. 8 In the present study ICAresults were binominal, no efforts were made to (semi)quantify ICA using a scoring system in order to reflect the routine clinical practice. The cut-off value was arbitrarily chosen at 10% staining. Results from EIA were quantitative. The cut-off value chosen to separate receptor-negative from receptor-positive tumours was 15 fmol/mg protein, according to the instructions of the manufacturer of the antibodies. But, the prognostic value of continuous variables, such as ER and PR, may be influenced by the cut-off level chosen. 25 Therefore, other cut-off values were studied. No significant differences in prognostic value of different cut-off values were found.
To our knowledge there has been only one study comparing the predictive value of EIA and ICA . 15 No former studies have been conducted comparing the prognostic value ER and PR as determined by either EIA or ICA. In the present study we prospectively evaluated the prognostic value detected both by ICA and by EIA of ER in 223 and of PR in 207 breast cancer patients after a median follow-up of 86 months. Both ER and PR appeared to be weak prognostic factors.
No differences in prognostic value according to time-point of analysis or cut-off value chosen were found. No differences in prognostic value of hormone receptors detected by ICA or EIA were found. Both methods appear to be equivalent with respect to qualification and with respect to prognostic value.
